VYNE Therapeutics's total assets for Q3 2025 were $36.13M, a decrease of -19.20% from the previous quarter. VYNE total liabilities were $4.04M for the fiscal quarter, a -30.71% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.